FDA approves InnoPharma’s acetylcysteine inhalation solution

The FDA has approved InnoPharma’s ANDA for acetylcysteine solution. The New Jersey company has a deal with Fresenius Kabi USA to market acetylcysteine solution in the US, where there has been a shortage of the product. Bedford Laboratories recalled acetylcysteine solution earlier this year and American Regent/Luitpold has experienced recurring manufacturing problems.

According to the company, it will make acetylcysteine solution, 20% concentration in 30 ml vials, available within a few weeks.

Read the InnoPharma press release.

Share

published on

May 10-May 14RDD 2026, Phoenix, AZ, USA

May 15-May 16: ATS Respiratory Innovation Summit 2026, Orlando, FL, USA

May 17-May 20: ATS International Conference 2026, Orlando, FL, USA

June 10SMI.London 2026, London, UK

July 13-July 162026 ISAM Congress, Taipei, Taiwan